We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Surgery for Aortic Regurgitation now Safer

By HospiMedica staff writers
Posted on 07 May 2007
The outcomes following aortic valve surgery for chronic aortic regurgitation (AR) with severe left ventricular dysfunction (LVD) have shown great improvement, and the procedure is no longer considered a high-risk procedure, concluded a new study. More...


Researchers at the Cleveland Clinic (OH, USA) studied data on 724 patients who underwent surgery for chronic aortic regurgitation between 1972 and 1999. Of these patients, 88 (12%) had an LV ejection fraction of 30% or less, while the others had higher ejection fractions. Across the entire study time frame, survival was lower among patients with severe LVD than among those with non-severe LVD. For example, estimated survival at one year was 81% versus 92% and at 25 years, 5% versus 12%. Over time, however, there was a dramatic improvement in survival in patients with severe LVD. In-hospital mortality fell from 50% in 1975 to none after 1985, and patients with severe and non-severe LVD treated after that year had equivalent survival. The study was reported in the April 3, 2007, issue of the Journal of the American College of Cardiology.

"Neutralizing risk of severe LVD has improved early and late survival such that aortic valve surgery for chronic AR and cardiomyopathy is no longer a high-risk procedure for which transplantation is the best option,” concluded senior author Dr. Sunil K. Bhudia and colleagues.

"The new study helps undo the old perception that many patients are too high risk for conventional surgery, and can only benefit from a heart transplant,” said Dr. Paul A. Grayburn, from Baylor University (Dallas, TX, USA), the author of an accompanying editorial. "Today we routinely operate on patients with advanced heart disease, and they face a risk that is only a fraction of what was reported years ago--but the public and other doctors are largely unaware of the new results.”


Related Links:
The Cleveland Clinic

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.